Vistagen Therapeutics Inc (VTGN)
0.57
+1.38%
Vistagen Therapeutics Inc (VTGN) is currently trading at $0.57. This represents a gain of 1.38% from the previous session. With a market capitalization of $0.02B, VTGN is a key component of the Health Care sector. Investors looking to trade VTGN should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Get 15 Free Stocks on Moomoo →
T&Cs Apply. Trade VTGN commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Vistagen Therapeutics Inc (VTGN) shows a bullish trend. Analysts are watching the 0.58 level closely.
Fundamentals
Mkt Cap0.02B
P/E Ratio0.0000
Volume261,745
60-Day Technical Chart
Advanced Charting
Need more indicators for VTGN? Use the world's #1 platform.
Open VTGN on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $1
| Metric |
VTGN +1.38% |
NXXT +1.37% |
ARAY -2.60% |
ADV +8.41% |
|---|---|---|---|---|
| Price | $0.57 | $0.58 | $0.58 | $0.54 |
| Mkt Cap | $0.02B | $0.08B | $0.07B | $0.18B |
| - | View → | View → | View → |
Latest Headlines
Vistagen CEO to give corporate overview at TD Cowen healthcare event
Stock Titan • Feb 25, 2026
VTGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026
PR Newswire • Feb 21, 2026
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Vistagen
GlobeNewswire • Feb 21, 2026
Is Vistagen Therapeutics (NASDAQ:VTGN) In A Good Position To Invest In Growth?
Yahoo Finance • Sep 27, 2025
Vistagen stock plummets after failed anxiety treatment trial
Investing.com • Dec 17, 2025
● Gemini Agentic AI Analyst Insight for VTGN
Market Education
- Trump’s New Tariffs Could Push Up Kitchen Renovation Costs Sep 26, 2025
- Exploring Gann Trading: An Insightful Guide for Traders Jun 2, 2024
- Long Short Strategy to Manage Risk May 31, 2024
External Research